home / stock / inzy / inzy quote
Last: | $4.49 |
---|---|
Change Percent: | 0.0% |
Open: | $4.46 |
Close: | $4.49 |
High: | $4.55 |
Low: | $4.43 |
Volume: | 197,852 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.49 | $4.46 | $4.49 | $4.55 | $4.43 | 197,852 | 07-04-2024 |
$4.49 | $4.46 | $4.49 | $4.55 | $4.43 | 197,852 | 07-03-2024 |
$4.42 | $4.61 | $4.42 | $4.665 | $4.32 | 505,123 | 07-02-2024 |
$4.41 | $4.45 | $4.41 | $4.51 | $4.345 | 393,671 | 07-01-2024 |
$4.46 | $4.53 | $4.46 | $4.535 | $4.39 | 1,055,760 | 06-28-2024 |
$4.52 | $4.43 | $4.52 | $4.58 | $4.405 | 182,863 | 06-27-2024 |
$4.42 | $4.37 | $4.42 | $4.47 | $4.35 | 260,294 | 06-26-2024 |
$4.37 | $4.45 | $4.37 | $4.52 | $4.34 | 476,820 | 06-25-2024 |
$4.48 | $4.51 | $4.48 | $4.66 | $4.435 | 384,287 | 06-24-2024 |
$4.45 | $4.38 | $4.45 | $4.4804 | $4.38 | 617,483 | 06-21-2024 |
$4.4 | $4.35 | $4.4 | $4.445 | $4.335 | 509,565 | 06-20-2024 |
$4.4 | $4.59 | $4.4 | $4.62 | $4.24 | 430,297 | 06-19-2024 |
$4.4 | $4.59 | $4.4 | $4.62 | $4.24 | 430,297 | 06-18-2024 |
$4.6 | $4.72 | $4.6 | $4.72 | $4.58 | 214,230 | 06-17-2024 |
$4.74 | $4.76 | $4.74 | $4.8 | $4.64 | 218,848 | 06-14-2024 |
$4.85 | $5 | $4.85 | $5.07 | $4.73 | 290,144 | 06-13-2024 |
$5 | $4.85 | $5 | $5.04 | $4.837 | 281,090 | 06-12-2024 |
$4.72 | $4.75 | $4.72 | $4.78 | $4.66 | 237,400 | 06-11-2024 |
$4.77 | $4.61 | $4.77 | $4.79 | $4.57 | 261,890 | 06-10-2024 |
$4.63 | $4.74 | $4.63 | $4.835 | $4.61 | 245,112 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation...